Design Therapeutics, Inc.
DSGN
Rank in Stocks
#10576
Design Therapeutics, Inc. is a biopharmaceutical company in the preclinical... Design Therapeutics, Inc. is a biopharmaceutical company in the preclinical phase that focuses on creating treatments for genetic conditions stemming from nucleotide repeat expansions. Its current pipeline targets Friedreich's Ataxia (FA), a severe, progressive, monogenic, and autosomal recessive disease. FA primarily impairs mitochondrial function across various organ systems, resulting in neurological, cardiac, and metabolic complications. Another significant area of development is Myotonic Dystrophy Type-1 (DM1). This is a progressive, dominantly inherited monogenic neuromuscular illness that impacts skeletal muscle, the heart, brain, and other bodily systems. Beyond these, the company is advancing its GeneTAC product candidate platform to address an array of other monogenic conditions caused by nucleotide repeat expansions. These include Fragile X syndrome, various spinocerebellar ataxias, amyotrophic lateral sclerosis (ALS), frontotemporal dementia, Huntington's disease, and spinobulbar muscular atrophy. Established in 2017, Design Therapeutics, Inc. maintains its headquarters in Carlsbad, California.
Share Price
$10.80
Last synced: 2026-11-09
Market Cap
$675.88M
Change (1 day)
5.78%
Change (1 year)
39.18%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Design Therapeutics, Inc. (DSGN)
Category
Healthcare
EPS for Design Therapeutics, Inc. (DSGN)
EPS as of September 2026 TTM: $-1.20
According to Design Therapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $-1.20. At the end of 2025 the company had an EPS of $-1.22, a decrease compared to its 2024 EPS of $-0.88.
EPS history for Design Therapeutics, Inc. from 2019 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-1.20 | -1.64% |
| 2025 | $-1.22 | 38.64% |
| 2024 | $-0.88 | -26.05% |
| 2023 | $-1.19 | 4.39% |
| 2022 | $-1.14 | 48.05% |
| 2021 | $-0.77 | 156.67% |
| 2020 | $-0.30 | 298.41% |
| 2019 | $-0.08 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -1,405.00% |
US
|
|
| $-7.07 | 489.17% |
US
|
|
| $-5.29 | 340.83% |
AU
|
|
| $12.88 | -1,173.34% |
BE
|
|
| $21.56 | -1,896.67% |
NL
|
Questions about Design Therapeutics, Inc.'s earnings per share (EPS)
What is Design Therapeutics, Inc.'s earnings per share (EPS)?
Design Therapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $-1.20, as of Sep 2026.
What was Design Therapeutics, Inc.'s earnings per share (EPS) in 2025?
In 2025, Design Therapeutics, Inc.'s earnings per share (EPS) was $-1.22, compared with $-0.88 in 2024.
How has Design Therapeutics, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Design Therapeutics, Inc.'s earnings per share (EPS) was highest in 2020 ($-0.30) and lowest in 2025 ($-1.22).
How does Design Therapeutics, Inc.'s earnings per share (EPS) compare with similar companies?
Design Therapeutics, Inc.'s earnings per share (EPS) ($-1.20) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.